Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.19
LH's Cash to Debt is ranked higher than
50% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. LH: 0.19 )
LH' s 10-Year Cash to Debt Range
Min: 0.02   Max: 0.59
Current: 0.19

0.02
0.59
Equity to Asset 0.38
LH's Equity to Asset is ranked higher than
58% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. LH: 0.38 )
LH' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.63
Current: 0.38

0.14
0.63
Interest Coverage 10.27
LH's Interest Coverage is ranked higher than
56% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. LH: 10.27 )
LH' s 10-Year Interest Coverage Range
Min: 1.03   Max: 22.66
Current: 10.27

1.03
22.66
F-Score: 6
Z-Score: 3.32
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.27
LH's Operating margin (%) is ranked higher than
93% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. LH: 15.27 )
LH' s 10-Year Operating margin (%) Range
Min: -4.39   Max: 19.94
Current: 15.27

-4.39
19.94
Net-margin (%) 8.72
LH's Net-margin (%) is ranked higher than
88% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. LH: 8.72 )
LH' s 10-Year Net-margin (%) Range
Min: -9.16   Max: 12.02
Current: 8.72

-9.16
12.02
ROE (%) 19.94
LH's ROE (%) is ranked higher than
96% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. LH: 19.94 )
LH' s 10-Year ROE (%) Range
Min: -45.84   Max: 28.64
Current: 19.94

-45.84
28.64
ROA (%) 7.39
LH's ROA (%) is ranked higher than
89% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. LH: 7.39 )
LH' s 10-Year ROA (%) Range
Min: -8.18   Max: 11.43
Current: 7.39

-8.18
11.43
ROC (Joel Greenblatt) (%) 77.88
LH's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. LH: 77.88 )
LH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10.63   Max: 137.1
Current: 77.88

-10.63
137.1
Revenue Growth (3Y)(%) 10.00
LH's Revenue Growth (3Y)(%) is ranked higher than
83% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. LH: 10.00 )
LH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.4   Max: 20
Current: 10

-21.4
20
EBITDA Growth (3Y)(%) 6.30
LH's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. LH: 6.30 )
LH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.3   Max: 17.6
Current: 6.3

-8.3
17.6
EPS Growth (3Y)(%) 5.60
LH's EPS Growth (3Y)(%) is ranked higher than
79% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. LH: 5.60 )
LH' s 10-Year EPS Growth (3Y)(%) Range
Min: 5.6   Max: 82.8
Current: 5.6

5.6
82.8
» LH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

LH Guru Trades in Q4 2013

John Hussman 200,000 sh (New)
First Pacific Advisors 84,500 sh (New)
Paul Tudor Jones 3,800 sh (New)
Scott Black 102,325 sh (+1134.62%)
Joel Greenblatt 140,973 sh (+425.86%)
Steven Cohen 18,012 sh (+292.93%)
Wallace Weitz 903,010 sh (+32.7%)
Chris Davis 9,561,830 sh (+21.11%)
Charles Brandes 144,040 sh (+16.51%)
Richard Pzena 2,405,081 sh (+4.13%)
Mark Hillman 7,339 sh (+1.56%)
Westport Asset Management 150,000 sh (unchged)
Mario Gabelli 4,170 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Jeremy Grantham 1,115,269 sh (-11.92%)
» More
Q1 2014

LH Guru Trades in Q1 2014

David Dreman 718 sh (New)
Ray Dalio 8,032 sh (New)
John Rogers 1,027,635 sh (New)
Larry Robbins 1,073,169 sh (New)
Jeff Auxier 4,780 sh (New)
Steven Cohen 40,037 sh (+122.28%)
Wallace Weitz 997,770 sh (+10.49%)
Charles Brandes 148,725 sh (+3.25%)
Chris Davis 9,638,047 sh (+0.8%)
First Pacific Advisors 84,500 sh (unchged)
Westport Asset Management 150,000 sh (unchged)
Paul Tudor Jones Sold Out
Scott Black 102,148 sh (-0.17%)
Mario Gabelli 4,000 sh (-4.08%)
Richard Pzena 2,256,910 sh (-6.16%)
Jeremy Grantham 966,113 sh (-13.37%)
Joel Greenblatt 59,243 sh (-57.98%)
John Hussman 62,900 sh (-68.55%)
» More
Q2 2014

LH Guru Trades in Q2 2014

Tom Gayner 15,000 sh (New)
Paul Tudor Jones 7,020 sh (New)
Louis Moore Bacon 3,935 sh (New)
Ray Dalio 31,466 sh (+291.76%)
John Rogers 1,087,739 sh (+5.85%)
Charles Brandes 154,198 sh (+3.68%)
Wallace Weitz 999,816 sh (+0.21%)
Mario Gabelli 4,000 sh (unchged)
First Pacific Advisors 84,500 sh (unchged)
John Hussman 62,900 sh (unchged)
David Dreman Sold Out
Larry Robbins Sold Out
Jeff Auxier 4,630 sh (-3.14%)
Westport Asset Management 140,000 sh (-6.67%)
Scott Black 79,092 sh (-22.57%)
Richard Pzena 1,654,529 sh (-26.69%)
Chris Davis 6,747,256 sh (-29.99%)
Jeremy Grantham 213,871 sh (-77.86%)
Joel Greenblatt 2,725 sh (-95.4%)
» More
Q3 2014

LH Guru Trades in Q3 2014

Jim Simons 238,200 sh (New)
Joel Greenblatt 317,530 sh (+11552.5%)
Ray Dalio 54,536 sh (+73.32%)
John Rogers 1,389,464 sh (+27.74%)
First Pacific Advisors 99,500 sh (+17.75%)
Charles Brandes 165,695 sh (+7.46%)
Jeff Auxier 4,630 sh (unchged)
John Hussman 62,900 sh (unchged)
Tom Gayner 15,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
Westport Asset Management 140,000 sh (unchged)
Louis Moore Bacon Sold Out
Wallace Weitz 988,891 sh (-1.09%)
Richard Pzena 1,558,296 sh (-5.82%)
Chris Davis 5,989,780 sh (-11.23%)
Scott Black 69,949 sh (-11.56%)
Paul Tudor Jones 4,047 sh (-42.35%)
Jeremy Grantham 122,271 sh (-42.83%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2014-09-30 Add 27.74%0.39%$102.01 - $108.25 $ 105.80%1389464
Joel Greenblatt 2014-09-30 Add 11552.5%0.32%$102.01 - $108.25 $ 105.80%317530
Chris Davis 2014-09-30 Reduce -11.23%0.24%$102.01 - $108.25 $ 105.80%5989780
Scott Black 2014-09-30 Reduce -11.56%0.14%$102.01 - $108.25 $ 105.80%69949
Ray Dalio 2014-09-30 Add 73.32%0.02%$102.01 - $108.25 $ 105.80%54536
Chris Davis 2014-06-30 Reduce -29.99%0.78%$98.21 - $104.67 $ 105.85%6747256
Richard Pzena 2014-06-30 Reduce -26.69%0.35%$98.21 - $104.67 $ 105.85%1654529
Scott Black 2014-06-30 Reduce -22.57%0.25%$98.21 - $104.67 $ 105.85%79092
Joel Greenblatt 2014-06-30 Reduce -95.4%0.08%$98.21 - $104.67 $ 105.85%2725
Tom Gayner 2014-06-30 New Buy0.04%$98.21 - $104.67 $ 105.85%15000
Ray Dalio 2014-06-30 Add 291.76%0.02%$98.21 - $104.67 $ 105.85%31466
David Dreman 2014-06-30 Sold Out 0.01%$98.21 - $104.67 $ 105.85%0
John Rogers 2014-03-31 New Buy1.2%$87.86 - $98.64 $ 105.814%1027635
John Hussman 2014-03-31 Reduce -68.55%0.89%$87.86 - $98.64 $ 105.814%62900
Wallace Weitz 2014-03-31 Add 10.49%0.29%$87.86 - $98.64 $ 105.814%997770
Joel Greenblatt 2014-03-31 Reduce -57.98%0.18%$87.86 - $98.64 $ 105.814%59243
Ray Dalio 2014-03-31 New Buy0.01%$87.86 - $98.64 $ 105.814%8032
David Dreman 2014-03-31 New Buy0.01%$87.86 - $98.64 $ 105.814%718
John Hussman 2013-12-31 New Buy1.3%$87.75 - $107.39 $ 105.86%200000
Scott Black 2013-12-31 Add 1134.62%0.92%$87.75 - $107.39 $ 105.86%102325
Wallace Weitz 2013-12-31 Add 32.7%0.69%$87.75 - $107.39 $ 105.86%903010
Chris Davis 2013-12-31 Add 21.11%0.37%$87.75 - $107.39 $ 105.86%9561830
Joel Greenblatt 2013-12-31 Add 425.86%0.25%$87.75 - $107.39 $ 105.86%140973
Ray Dalio 2013-12-31 Sold Out 0.03%$87.75 - $107.39 $ 105.86%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Laboratory Corp of America Hldgs

John Rogers Comments on Laboratory Corp. of America Holdings - May 07, 2014

We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Laboratory Corp of America Hldgs

The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Top Five Guru-Owned Mid Cap Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
John Rogers Comments on Laboratory Corp. of America Holdings
We purchased a previous holding in our mid ca p fund, Laboratory Corp. of America Holdings (LH). LabCorp maintains a leading market position in an indust ry that continues to show promising growth potential du e to technological advances, aging demographics, health care cost containment, and preventative medicine. LabCorp maintains a solid balance sheet, generates a significant amount of free cash flow and has been returning value to shareholders through share repurchases. The company operates with an experienced management team that is conservative yet willing to take slight risks in order to grow the business long-term. Read more...
GuruFocus Real Time Picks of the Week
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The “Real Time Picks” reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases in Real Time activity from Seth Klarman (Trades, Portfolio), Jean-Marie Eveillard (Trades, Portfolio) and Chris Davis (Trades, Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.70
LH's P/E(ttm) is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 17.70 )
LH' s 10-Year P/E(ttm) Range
Min: 12.98   Max: 24.73
Current: 17.7

12.98
24.73
P/B 3.24
LH's P/B is ranked higher than
77% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. LH: 3.24 )
LH' s 10-Year P/B Range
Min: 2.69   Max: 5.41
Current: 3.24

2.69
5.41
P/S 1.55
LH's P/S is ranked higher than
86% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. LH: 1.55 )
LH' s 10-Year P/S Range
Min: 1.33   Max: 2.97
Current: 1.55

1.33
2.97
PFCF 16.53
LH's PFCF is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 16.53 )
LH' s 10-Year PFCF Range
Min: 9.15   Max: 20.72
Current: 16.53

9.15
20.72
EV-to-EBIT 12.57
LH's EV-to-EBIT is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 12.57 )
LH' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 16.2
Current: 12.57

8.8
16.2
PEG 2.60
LH's PEG is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 2.60 )
LH' s 10-Year PEG Range
Min: 0.82   Max: 166.25
Current: 2.6

0.82
166.25
Shiller P/E 18.31
LH's Shiller P/E is ranked higher than
98% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 18.31 )
LH' s 10-Year Shiller P/E Range
Min: 16.13   Max: 36.5
Current: 18.31

16.13
36.5
Current Ratio 2.25
LH's Current Ratio is ranked higher than
68% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. LH: 2.25 )
LH' s 10-Year Current Ratio Range
Min: 0.47   Max: 3.64
Current: 2.25

0.47
3.64
Quick Ratio 2.07
LH's Quick Ratio is ranked higher than
70% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. LH: 2.07 )
LH' s 10-Year Quick Ratio Range
Min: 0.44   Max: 3.45
Current: 2.07

0.44
3.45

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.85
LH's Price/DCF (Projected) is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 0.85 )
LH' s 10-Year Price/DCF (Projected) Range
Min: 0.68   Max: 6.11
Current: 0.85

0.68
6.11
Price/Median PS Value 0.87
LH's Price/Median PS Value is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. LH: 0.87 )
LH' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 1.68
Current: 0.87

0.07
1.68
Price/Peter Lynch Fair Value 2.87
LH's Price/Peter Lynch Fair Value is ranked higher than
92% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 2.87 )
LH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.86   Max: 3.83
Current: 2.87

0.86
3.83
Earnings Yield (Greenblatt) 8.00
LH's Earnings Yield (Greenblatt) is ranked higher than
94% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. LH: 8.00 )
LH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.2   Max: 11.3
Current: 8

6.2
11.3
Forward Rate of Return (Yacktman) 12.55
LH's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. LH: 12.55 )
LH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.7   Max: 23.6
Current: 12.55

5.7
23.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ALR, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs, founded in 1971, is an independent clinical laboratory company in the United States. Since the Companys founding, it has grown into a national network of 54 primary laboratories and over 1,700 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Companys strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Specialty Cancer, Hospitals and Primary Care. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
» More Articles for LH

Headlines

Articles On GuruFocus.com
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Tom Gayner’s Top 5 New Portfolio Picks Aug 11 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
John Rogers Comments on Laboratory Corp. of America Holdings May 07 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historic Low P/S May 06 2014 
John Rogers' Ariel Appreciation Fund First Quarter 2014 Commentary Apr 30 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/S Apr 15 2014 
Morning Coffee: Guru Stocks Near Their Historical Low P/S Apr 03 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 

More From Other Websites
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Dec 18 2014
LabCorp Introduces a Test to Identify Enterovirus D-68 (EV-D68) Dec 18 2014
LabCorp Introduces a Test to Identify Enterovirus D-68 (EV-D68) Dec 18 2014
LabCorp Named Laboratory Service Provider of the Pro Football Legends Dec 17 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Dec 17 2014
LabCorp Named Laboratory Service Provider of the Pro Football Legends Dec 17 2014
LabCorp Named Laboratory Service Provider of the Pro Football Legends Dec 17 2014
Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance Dec 16 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Dec 16 2014
Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance Dec 16 2014
LabCorp Buys DNA Testing Firm, Expands Forensics Business Dec 08 2014
Advanced Animal Diagnostics Closes $15 Million in Oversubscribed Series C Funding Dec 08 2014
Investor Lawsuit Against Takeover of Covance Inc. (CVD) Announced by Shareholders Foundation Dec 08 2014
LabCorp Announces Acquisition of Bode Technology Dec 05 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Dec 05 2014
LabCorp Announces Acquisition of Bode Technology Dec 05 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Other Events, Financial Statements and... Dec 04 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Change in Directors or Principal Officers Dec 03 2014
LabCorp Completes Acquisition of LIPOSCIENCE Nov 21 2014
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Nov 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK